Neuropathies douloureuses et atteinte des petites fibres

It is customary to consider that a purely sensory and painful neuropathy accompanied by normal electroneuromyographic examination may be or must be a small fiber neuropathy. This leads to perform specific tests, such as measuring the intra-epidermal nerve fiber density on skin biopsy or neurophysiological tests, such as evoked potentials to noxious stimuli (laser) or quantification of thermal sensory thresholds. However, these tests are only sensitive to the loss of small fibers (A-delta and C), which does not reflect the mechanisms responsible for peripheral neuropathic pain. Selective loss of small sensory fibers inherently generates a sensory deficit that does not necessarily present a painful character. Also, assigning the cause of a painful neuropathy to a small fiber neuropathy has no pathophysiological sense, although there are indirect links between these two conditions. In fact, it is not possible to explain univocally peripheral neuropathic pain, which reflects complex and diverse mechanisms, involving different types of nerve fibers. In this context, the clinical and laboratory approach must be improved to better understand the underlying mechanisms. It is imperative to interpret the data provided by laboratory tests and to correlate these data to the clinical signs and symptoms presented by the patients. Thus, one must go beyond many a priori and misinterpretations that unfortunately exist in this area at present and are not based on any solid pathophysiological basis.     

Type I complex regional pain syndrome

First described by Ambroise Paré in the mid-17th century complex, regional pain syndrome (CRPS) can be defined as an articular and periarticular pain syndrome associated with vasomotor deregulation triggered by various stresses with no relationship between the intensity of the initial injury and severity of the continuing pain. Several names have been given to Type 1 complex regional pain syndrome (CRPS-I): causalgia, reflex sympathetic dystrophy, shoulder-hand syndrome and algodystrophy. The reported incidence of CRPS-I is about 25 per 100,000. Predisposing factors are tobacco consumption and being female (W/M ratio = 4). Although all the limbs can be affected, the upper limb is by far the most affected. CRPS-I is a classic complication of distal radius fractures (4–37%) and carpal tunnel surgery (2–4%). Early diagnosis and management are the most important elements of treatment because this syndrome has a long and disabling course. Some of the proposed treatments include NSAIDs, antidepressants and anticonvulsants. The latter, despite their good analgesic effects, do not cure CRPS-I. In select cases, a surgical procedure aiming at removing a nociceptive stimulus can lead to spectacular improvements.     

Endovenous Glue-Induced Thrombosis in Nonthermal Glue Closure Therapy for Greater Saphenous Vein Insufficiency: A Single-Center Experience

A retrospective analysis of endovenous glue-closure therapy (EVGC) performed in 76 greater saphenous veins (GSVs) from February 2016 to December 2017 was conducted to assess the incidence and characteristics of endovenous glue-induced thrombosis (EGIT), a phenomenon unique to nonthermal EVGC for GSV insufficiency. Kabnick and Lawrence classifications for endovenous heat-induced thrombosis were adopted. Seven instances of EGIT were detected among 54 patients (13%), with median/mode Kabnick and Lawrence classifications of 2/2 and 4/5, respectively. EGIT resolved with observation within an average of 5.2 wk after detection (range, 2–8 wk) without deep vein thrombosis or pulmonary embolism. EGIT was associated with significantly greater mean age (+7.75 y; P = .0308).     

围术期戒烟病理生理与国内外麻醉医师对戒烟干预研究进展

背景 吸烟患者在围术期均处于不同的戒烟期,麻醉医师在围术期承担重要角色,但戒烟对围术期病理生理的影响有多大,哪些因素影响患者的围术期戒烟及戒烟实施情况并不十分清楚. 目的 提高麻醉管理水平,改善围术期吸烟患者的预后. 内容 回顾当前关于短期(时间范围从数小时到数周)和长期戒烟病理生理方面的变化,尤其是与术后转归密切相关的几个方面.此外,还探讨围术期戒烟的影响因素、国内外麻醉医师在围术期戒烟中的作用与实践. 趋向 围术期戒烟还有很长的路要走,需要今后的临床研究和实验进一步探讨,以便更好地帮助患者围术期甚至长期戒烟,减少麻醉手术相关并发症.     

Colon ischemia: A comprehensive review

The clinical and endoscopic features of colon ischemia (CI) are non-specific. CI is correctly identified at the time of presentation in only 9% of patients is. The true incidence is likely underestimated because many mild cases resolve spontaneously without medical treatment. Furthermore, since most cases of CI are transient, and no specific cause is detected they are often considered to be “idiopathic”. In the setting of severe CI correct diagnosis and prompt recognition and therapy as well as identification of underlying causes are crucial for a favourable outcome. Although less severe, mild cases may present with similar symptoms, the prognosis and management are completely different and managed conservatively rather than with surgery. Unfortunately, data from most studies and current guidelines do not provide recommendations on the long-term management of CI or about the need for endoscopic follow-up to detect the development chronic, recurrent and/or ischemic colonic strictures. In this review, we focus on the definition of CI, its aetiology, and patterns of presentation. We highlight the pharmacological and/or endoscopic management as determined severity of disease that allow for improved outcomes. Prompt recognition and treatment using a multidisciplinary approach are essential for successful management of severe CI because mortality rates are significantly higher when the diagnosis is delayed.     

The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder

The immune hypothesis of major depressive disorder (MDD) fits well with the supposed interaction between genetic and environmental factors in disorders with a complicated etiopathogenesis. It has been suggested that infectious diseases are associated with MDD in that cytokines may play a critical role as a key modulator in the transition between infection and the development of MDD. It has been also suggested that antidepressants have immunomodulatory effects on some cytokines and cytokine receptors, although the exact mechanism has not yet been fully elucidated. Among cytokines, monocyte chemoattractant protein-1 (MCP-1) is especially well known and has attracted considerable interest owing to its immunomodulatory functions. MCP-1 is expressed in highly regionalized neuronal areas in the brain, leading to kind of modulation of neuronal activity and neuroendocrine functions commonly seen in patients with MDD. Additionally, it is involved in the control of other cytokines that have been consistently proposed as associated with the development of MDD. It also has a possible role in the neurodegenerative process of a number of central nervous system (CNS) diseases. Hence, this paper draws from the perspective of immunology to offer several suggestions about the role of MPC-1 in the development of MDD.